Review Article
Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: An Overview of Systematic Reviews
Table 3
Quality of evidence in included reviews with GRADE.
| | Author (Y) | Intervention (treatment group vs control group) | Outcomes (n) | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Quality of evidence |
| | Hoffman (2021) [36] | SCT (allo-SCT, auto-SCT, undefined type of SCT) vs chemotherapy | CR2 (12) | 0 | −1 | 0 | 0 | 0 | M | | OS (12) | 0 | −1 | 0 | 0 | 0 | M | | Li (2019) [27] | Auto-SCT vs allo-SCT | RFS (10) | 0 | −1 | 0 | 0 | 0 | M | | OS (10) | 0 | −1 | 0 | 0 | 0 | M | | RR (7) | 0 | 0 | 0 | 0 | 0 | H | | TRM (4) | 0 | 0 | 0 | 0 | 0 | H | | Rashidi (2016) [28] | Allo-SCT vs further chemotherapy or no treatment | RFS (10) | 0 | 0 | 0 | −1 | 0 | M | | OS (12) | 0 | 0 | 0 | −1 | 0 | M | | Ma (2015) [25] | Allo-SCT/auto-SCT vs chemotherapy; allo-SCT vs auto-SCT | OS (9) | −1 | −1 | 0 | 0 | 0 | L | | RR (4) | −1 | 0 | 0 | 0 | 0 | M | | DFS (5) | −1 | −1 | 0 | 0 | 0 | L | | Li (2015) [26] | Allo-SCT vs auto-SCT or (and) chemotherapy | RFS (6) | −1 | −1 | 0 | 0 | 0 | L | | RR (8) | −1 | 0 | 0 | 0 | 0 | M | | TRM (4) | −1 | 0 | 0 | 0 | 0 | M | | OS (4) | −1 | −1 | 0 | 0 | 0 | L | | Jing (2010) [29] | Auto-SCT vs further chemotherapy or no treatment | OS (11) | −1 | −1 | 0 | 0 | 0 | L | | RR (11) | −1 | −1 | 0 | 0 | 0 | L | | DFS (13) | −1 | −1 | 0 | 0 | 0 | L | | TRM (11) | −1 | −1 | 0 | 0 | 0 | L | | Survival from relapse (3) | −1 | 0 | 0 | 0 | 0 | M | | Krauter (2009) [30] | Allo-SCT vs auto-SCT or (and) chemotherapy | OS | 0 | 0 | 0 | 0 | 0 | H | | RFS | 0 | 0 | 0 | 0 | 0 | H | | Koreth (2009) [31] | Allo-SCT vs auto-SCT or (and) chemotherapy | OS (15) | −1 | −1 | 0 | 0 | 0 | L | | RFS (18) | −1 | −1 | 0 | 0 | 0 | L | | Schaich (2007) [32] | High-dose cytarabine + allo-SCT/auto-SCT vs high-dose cytarabine | OS | 0 | 0 | 0 | 0 | 0 | H | | RFS | 0 | 0 | 0 | 0 | 0 | H | | Nathan (2004) [33] | ABMT vs nonmyeloablative chemotherapy or no further treatment | OS (5) | −1 | −1 | 0 | 0 | −1 | L | | TRM (6) | −1 | 0 | 0 | 0 | −1 | L | | DFS (6) | −1 | 0 | 0 | 0 | −1 | L | | Levi (2004) [34] | ABMT vs chemotherapy | Death rate (6) | 0 | −1 | 0 | 0 | −1 | L | | Death or relapse rate(6) | 0 | 0 | 0 | 0 | −1 | M | | Bleakley (2002) [35] | ABMT vs BMT (MSD)/ABMT vs nonmyeloablative chemotherapy | RR (3) | 0 | 0 | 0 | 0 | −1 | M | | Death rate (3) | 0 | 0 | 0 | 0 | −1 | M | | Death or relapse rate (4) | 0 | 0 | 0 | 0 | −1 | M | | TRM (3) | 0 | −1 | 0 | 0 | −1 | L |
|
|
−1:serious(downgrade by one level); −2: extremely serious (downgrade by two levels); 0: not serious; H: high; M: moderate; L: low; CL: critically low CR2, second complete remission; OS, overall survival; DFS, disease-free survival; EFS, event-free survival; RFS, relapse-free survival; TRM, treatment-related mortality; RR, relapse rate.
|
